Novel treatments to help patients with central nervous system disorders


  • 2016-11-28
    - Uppsala University and BioArctic receive a MSEK 5 grant
    Read more »
  • 2016-11-22
    - Horizon 2020: BioArctic’s Spinal Cord Injury Project in focus at Game Plan Europe 2016
    Read more »
  • 2016-09-20
    - BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research
    Read more »



Antibodies targeting toxic proteins



First drug candidate in development for Alzheimer’s disease

Therapeutic Area


CNS disorders

Proud partner of

BioArctic enters a strategically important collaboration:

Aiming for a disease modifying treatment for Parkinson’s disease

Gunilla Osswald, CEO: “Our new partner AbbVie has shown a strong commitment to Parkinson’s disease and I am proud that they have chosen to collaborate with BioArctic. I am looking forward to a successful partnership that hopefully will result in a new, innovative disease modifying treatment becoming available to the large number of patients suffering from Parkinson’s disease.” Read more »